Cicin Fatma Nur, Cicin Irfan
Faculty of Economics, Administrative and Social Sciences, Department of Management Information Systems, Istinye University, Istanbul, Türkiye, Turkey.
Faculty of Medicine, Department of Medical Oncology, Istinye University, Istanbul, Türkiye, Turkey.
J Med Syst. 2025 Aug 8;49(1):103. doi: 10.1007/s10916-025-02233-9.
The integration of mobile health (mHealth) technologies into decentralized clinical trials (DCTs) may represent a paradigm shift in oncology research, offering innovative solutions to longstanding challenges in clinical trial design and execution. mHealth tools, including wearable biosensors, telemedicine platforms, and artificial intelligence (AI)-driven analytics, have the potential to enable real-time patient monitoring, support participant engagement, and facilitate remote data collection. Also, these advancements have the potential to improve recruitment rates, optimize treatment adherence, and ensure more equitable access to clinical trials, particularly for patients in underserved regions. Moreover, precision oncology approaches leveraging mHealth data may contribute to personalized treatment strategies that improve patient outcomes. However, regulatory complexities, data privacy concerns, and technological disparities remain critical challenges that must be addressed to ensure the widespread adoption of mHealth-enabled DCTs. Future advancements in AI, blockchain technology, and remote diagnostic tools may further enhance the scalability, efficiency, and inclusivity of these trials. By embracing these innovations, oncology research can transition toward a more patient-centric, data-driven paradigm that has the potential to accelerates drug development and enhances clinical decision-making. This narrative review explores the potentially transformative role of mHealth technologies in DCTs within oncology.
将移动健康（mHealth）技术整合到去中心化临床试验（DCTs）中，可能代表着肿瘤学研究的范式转变，为临床试验设计和实施中长期存在的挑战提供创新解决方案。移动健康工具，包括可穿戴生物传感器、远程医疗平台和人工智能（AI）驱动的分析，有可能实现对患者的实时监测，支持参与者参与，并促进远程数据收集。此外，这些进展有可能提高招募率，优化治疗依从性，并确保更公平地参与临床试验，特别是对于服务不足地区的患者。此外，利用移动健康数据的精准肿瘤学方法可能有助于制定个性化治疗策略，从而改善患者预后。然而，监管复杂性、数据隐私问题和技术差距仍然是必须解决的关键挑战，以确保广泛采用基于移动健康的去中心化临床试验。人工智能、区块链技术和远程诊断工具的未来进展可能会进一步提高这些试验的可扩展性、效率和包容性。通过采用这些创新，肿瘤学研究可以向更以患者为中心、数据驱动的范式转变，这有可能加速药物开发并加强临床决策。这篇叙述性综述探讨了移动健康技术在肿瘤学去中心化临床试验中的潜在变革性作用。
